- Home
- FIVN vs AUPH Comparison
FIVN vs AUPH Comparison
Compare FIVN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVN | AUPH |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FIVN | AUPH |
|---|---|---|
| Price | $17.93 | $14.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $26.32 | $17.25 |
| AVG Volume (30 Days) | ★ 2.9M | 872.5K |
| Earning Date | 05-21-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 364.71 | ★ 5075.00 |
| EPS | 0.45 | ★ 2.07 |
| Revenue | ★ $1,149,088,000.00 | $283,055,000.00 |
| Revenue This Year | $11.39 | $17.35 |
| Revenue Next Year | $10.00 | $15.66 |
| P/E Ratio | $40.24 | ★ $6.92 |
| Revenue Growth | 10.28 | ★ 20.38 |
| 52 Week Low | $15.70 | $6.83 |
| 52 Week High | $31.75 | $16.54 |
Technical Indicators
Market Signals| Indicator | FIVN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 47.23 |
| Support Level | $18.03 | $13.52 |
| Resistance Level | $18.96 | $16.28 |
| Average True Range (ATR) | 1.15 | 0.55 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 44.63 | 49.42 |
Price Performance
Historical ComparisonAbout FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.